Illumina Upgraded to Outperform by Wedbush (ILMN)
Illumina (NASDAQ:ILMN) was upgraded by research analysts at Wedbush from a “neutral” rating to an “outperform” rating in a report released on Wednesday, TheFlyOnTheWall.com reports.
A number of other analysts have also recently weighed in on ILMN. Analysts at Stifel Nicolaus initiated coverage on shares of Illumina in a research note on Monday, August 11th. They set a “buy” rating and a $200.00 price target on the stock. Separately, analysts at Goldman Sachs raised their price target on shares of Illumina from $184.00 to $187.00 in a research note on Tuesday, August 5th. Finally, analysts at Tigress Financial initiated coverage on shares of Illumina in a research note on Friday, August 1st. They set a “buy” rating on the stock. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $177.68.
In other Illumina news, SVP Nicholas Naclerio sold 2,000 shares of the stock on the open market in a transaction dated Friday, August 15th. The stock was sold at an average price of $167.23, for a total transaction of $334,460.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Illumina (NASDAQ:ILMN) opened at 170.49 on Wednesday. Illumina has a 1-year low of $72.77 and a 1-year high of $185.00. The stock has a 50-day moving average of $170.1 and a 200-day moving average of $160.3. The company has a market cap of $23.766 billion and a price-to-earnings ratio of 115.08.
Illumina (NASDAQ:ILMN) last announced its earnings results on Wednesday, July 23rd. The company reported $0.57 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.50 by $0.07. The company had revenue of $448.00 million for the quarter, compared to the consensus estimate of $426.50 million. During the same quarter in the prior year, the company posted $0.43 earnings per share. The company’s quarterly revenue was up 29.5% on a year-over-year basis. Analysts expect that Illumina will post $2.29 EPS for the current fiscal year.
Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.
Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.